Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can new biomarkers transform adrenal cancer treatment?

NCT ID NCT05754892

First seen Apr 04, 2026 · Last updated Jun 18, 2026 · Updated 7 times

Summary

This study aims to bring new molecular markers (biomarkers) into routine care for patients with rare adrenal cancers. Researchers will check if these markers can be delivered within 3 months after surgery and if they provide useful information. The goal is to see if these markers help doctors make better treatment decisions. About 450 adults with adrenal tumors will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • GH Paris Centre, Assistance Publique - Hôpitaux de Paris

    RECRUITING

    Paris, 75014, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

adrenal cortex carcinoma cancer malignant adrenal gland pheochromocytoma neoplasm paraganglioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.